Vertex Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Vertex Pharmaceuticals (Boston, MA): 9 reconciled FDA prescription therapies (4.3% 2025 to 2030 cliff risk), $2.45B 2024 CMS Part D & Medicaid spend, and $2,200,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Boston, MA |
| Reconciled FDA Portfolio Therapies | 9 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 4.3% |
| Primary Portfolio LOE Date | 2030-01-01 |
| 2024 CMS Total Public Spend | $2.45B |
| 2024 Medicare Part D Spend | $770.5M |
| 2024 Medicaid Spend | $1.67B |
| California HCAI SB 17 Filings | Specialty launch notice ($2,200,000 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.